Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Somatogen (SMTG) -- Ignore unavailable to you. Want to Upgrade?

To: RalphLStevens,MD who wrote (353)	1/9/1998 12:31:00 AM
From: Bharat H. Barai	Read Replies (1) \| Respond to of 442

Talked to Somatogen on 1-5-98. (1) The data from 1st phase of Cardiac Bypass study are in and being decoded. The data will be published by the end of this month. (2) There were no untoward side effects during the studies, suggesting good tolerability. (3) The Hematopoesis data are also being analysed. Results of those will be published by the end of this month. (4) Active discussions are continuing with SEVERAL potential corporate partners. Two of them are front runners. The potential partners will be given the latest data, once ready. They expect to finalise the partner before the end of June, 1998. My Personal note: (1) Hematopoesis data is really a side issue. If they come positive, it will be a big surprize. Even if positive, it is a relatively small field, as compared to transfusion arena. (2) To me most important in CPB study is tolearability. While other parts of study are being analysed, the fact that Optro was given and successfully tolerated is a big positive demonstration itself. B.H. Barai MD Hematologist